Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS +1.72% Net Cash per Share is A$0.11 as of Dec. 2025, which is 100% below its 10-year median of 5.30. The stock has 4 warning signs investors should review. Among 59 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 96.61% on this metric.
The historical rank and industry rank for Genetic Signatures's Net Cash per Share or its related term are showing as below:
ASX:GSS'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.54 Med: 5.3 Max: 51.77
Current: 0.54
During the past 11 years, the highest Price-to-Net-Cash Ratio of Genetic Signatures was 51.77. The lowest was 0.54. And the median was 5.30.
ASX:GSS's Price-to-Net-Cash is ranked better than 96.61% of 59
companies
in the Medical Diagnostics & Research industry
Industry Median: 8.43
vs ASX:GSS: 0.54
Genetic Signatures (ASX:GSS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Genetic Signatures Net Cash per Share Related Terms
Genetic Signatures Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Genetic Signatures's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Net Cash per Share of A$0.11 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Genetic Signatures and its competitors. This is 98% below median its historical median of 5.30. Over the past decade, Genetic Signatures' Net Cash per Share has ranged from 0.54 to 51.77. According to the industry distribution chart, Genetic Signatures ranks #2 out of 59 companies in the Medical Diagnostics & Research industry, placing it in the top 3.4%.
Is Genetic Signatures' Net Cash per Share too high?
Genetic Signatures' current Net Cash per Share of A$0.11 is 98% below median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 51.77. Based on the distribution chart, Genetic Signatures ranks #2 out of 59 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' Net Cash per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #2 out of 59 companies for Net Cash per Share. This places Genetic Signatures in the top 3% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 8.43. Historically, Genetic Signatures' own Net Cash per Share has ranged from 0.54 to 51.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 8.43, based on 59 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 8.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Net Cash per Share is A$0.11, which is 98% below median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.39, compared to a current price of A$0.06 — trading 84.9% below its estimated fair value. The current Net Cash per Share is A$0.11, which is 98% below median its 10-year median of 5.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Net Cash per Share is A$0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
